<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Wed, 22 Jul 2026 17:39:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Cenovus to hold second-quarter 2026 conference call  and webcast on July 29</title>
   <link>http://www.streetinsider.com/Press+Releases/Cenovus+to+hold+second-quarter+2026+conference+call++and+webcast+on+July+29/26802795.html</link>
   <description>
&lt;p&gt;CALGARY, Alberta, July  22, 2026  (GLOBE NEWSWIRE) -- Cenovus Energy Inc. (TSX:CVE) (NYSE:CVE) will release its second-quarter 2026 results on Wednesday, July 29, 2026. The news release will provide consolidated second-quarter operating and financial information. The company’s financial statements will be available on Cenovus’s website, &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=Mkpi5NqC6hioMWnMs49MEUi7ryQ-GZ3goUfb2lggkbJeQsBHUz65z0Ndx6g9a9CsTZVrInHCECcEQBFOgNBQxA==&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;cenovus.com&lt;/a&gt;.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;Second-quarter 2026 conference call: 9 a.m. MT (11 a.m. ET)&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;Analysts wishing to participate in the conference call are asked to &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=TSDNTYvbbqLpv1V1WbPHRIwfAf93Ek6r2MOT14l-oyAgrpCdFn9iblkOVT7vNd_Zh0EejbY6PBaqsG9n3itCSiknJ1UIFO56z2p22s8eBqmUGMQCTGRDkbGC5iRA9QD0o05gV241uuRZr76EQ7zHjZdaxj53FdwfHxW9J5gde7k=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;register&lt;/a&gt; in advance.&lt;/p&gt;  &lt;p&gt;To participate in the conference call, complete the online registration form before the call begins. Once registered, participants</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Cenovus+to+hold+second-quarter+2026+conference+call++and+webcast+on+July+29/26802795.html</guid>
   <pubDate>Wed, 22 Jul 2026 17:39:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.07618170</category>
   	  </item>
  <item>
   <title>Cenovus to hold second-quarter 2026 conference call  and webcast on July 29</title>
   <link>http://www.streetinsider.com/Press+Releases/Cenovus+to+hold+second-quarter+2026+conference+call++and+webcast+on+July+29/26802795.html</link>
   <description>
&lt;p&gt;CALGARY, Alberta, July  22, 2026  (GLOBE NEWSWIRE) -- Cenovus Energy Inc. (TSX:CVE) (NYSE:CVE) will release its second-quarter 2026 results on Wednesday, July 29, 2026. The news release will provide consolidated second-quarter operating and financial information. The company’s financial statements will be available on Cenovus’s website, &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=Mkpi5NqC6hioMWnMs49MEUi7ryQ-GZ3goUfb2lggkbJeQsBHUz65z0Ndx6g9a9CsTZVrInHCECcEQBFOgNBQxA==&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;cenovus.com&lt;/a&gt;.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;Second-quarter 2026 conference call: 9 a.m. MT (11 a.m. ET)&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;Analysts wishing to participate in the conference call are asked to &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=TSDNTYvbbqLpv1V1WbPHRIwfAf93Ek6r2MOT14l-oyAgrpCdFn9iblkOVT7vNd_Zh0EejbY6PBaqsG9n3itCSiknJ1UIFO56z2p22s8eBqmUGMQCTGRDkbGC5iRA9QD0o05gV241uuRZr76EQ7zHjZdaxj53FdwfHxW9J5gde7k=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;register&lt;/a&gt; in advance.&lt;/p&gt;  &lt;p&gt;To participate in the conference call, complete the online registration form before the call begins. Once registered, participants</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Cenovus+to+hold+second-quarter+2026+conference+call++and+webcast+on+July+29/26802795.html</guid>
   <pubDate>Wed, 22 Jul 2026 17:39:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.07618170</category>
   	  </item>
  <item>
   <title>Cenovus to hold second-quarter 2026 conference call  and webcast on July 29</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Cenovus+to+hold+second-quarter+2026+conference+call++and+webcast+on+July+29/26802795.html</link>
   <description>
&lt;p&gt;CALGARY, Alberta, July  22, 2026  (GLOBE NEWSWIRE) -- Cenovus Energy Inc. (TSX:CVE) (NYSE:CVE) will release its second-quarter 2026 results on Wednesday, July 29, 2026. The news release will provide consolidated second-quarter operating and financial information. The company’s financial statements will be available on Cenovus’s website, &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=Mkpi5NqC6hioMWnMs49MEUi7ryQ-GZ3goUfb2lggkbJeQsBHUz65z0Ndx6g9a9CsTZVrInHCECcEQBFOgNBQxA==&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;cenovus.com&lt;/a&gt;.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;Second-quarter 2026 conference call: 9 a.m. MT (11 a.m. ET)&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;Analysts wishing to participate in the conference call are asked to &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=TSDNTYvbbqLpv1V1WbPHRIwfAf93Ek6r2MOT14l-oyAgrpCdFn9iblkOVT7vNd_Zh0EejbY6PBaqsG9n3itCSiknJ1UIFO56z2p22s8eBqmUGMQCTGRDkbGC5iRA9QD0o05gV241uuRZr76EQ7zHjZdaxj53FdwfHxW9J5gde7k=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;register&lt;/a&gt; in advance.&lt;/p&gt;  &lt;p&gt;To participate in the conference call, complete the online registration form before the call begins. Once registered, participants</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Cenovus+to+hold+second-quarter+2026+conference+call++and+webcast+on+July+29/26802795.html</guid>
   <pubDate>Wed, 22 Jul 2026 17:39:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.07618170</category>
   	  </item>
  <item>
   <title>Cenovus to hold second-quarter 2026 conference call  and webcast on July 29</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Cenovus+to+hold+second-quarter+2026+conference+call++and+webcast+on+July+29/26802795.html</link>
   <description>
&lt;p&gt;CALGARY, Alberta, July  22, 2026  (GLOBE NEWSWIRE) -- Cenovus Energy Inc. (TSX:CVE) (NYSE:CVE) will release its second-quarter 2026 results on Wednesday, July 29, 2026. The news release will provide consolidated second-quarter operating and financial information. The company’s financial statements will be available on Cenovus’s website, &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=Mkpi5NqC6hioMWnMs49MEUi7ryQ-GZ3goUfb2lggkbJeQsBHUz65z0Ndx6g9a9CsTZVrInHCECcEQBFOgNBQxA==&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;cenovus.com&lt;/a&gt;.&lt;/p&gt;  &lt;p&gt;&lt;strong&gt;Second-quarter 2026 conference call: 9 a.m. MT (11 a.m. ET)&lt;/strong&gt;&lt;/p&gt;  &lt;p&gt;Analysts wishing to participate in the conference call are asked to &lt;a target=&quot;_blank&quot; href=&quot;https://www.globenewswire.com/Tracker?data=TSDNTYvbbqLpv1V1WbPHRIwfAf93Ek6r2MOT14l-oyAgrpCdFn9iblkOVT7vNd_Zh0EejbY6PBaqsG9n3itCSiknJ1UIFO56z2p22s8eBqmUGMQCTGRDkbGC5iRA9QD0o05gV241uuRZr76EQ7zHjZdaxj53FdwfHxW9J5gde7k=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;register&lt;/a&gt; in advance.&lt;/p&gt;  &lt;p&gt;To participate in the conference call, complete the online registration form before the call begins. Once registered, participants</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Cenovus+to+hold+second-quarter+2026+conference+call++and+webcast+on+July+29/26802795.html</guid>
   <pubDate>Wed, 22 Jul 2026 17:39:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.07618170</category>
   	  </item>
  <item>
   <title>Desjardins Starts Cenovus Energy Inc. (CVE:CN) (CVE) at Buy</title>
   <link>http://www.streetinsider.com/Intl+Ratings/Desjardins+Starts+Cenovus+Energy+Inc.+%28CVE%3ACN%29+%28CVE%29+at+Buy/26781616.html</link>
   <description>&lt;p&gt;Desjardins analyst Chris MacCulloch initiates coverage on Cenovus Energy Inc. (CVE:CN) (NYSE: CVE) with a Buy rating and a price target of Cdn$50.00.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/Desjardins+Starts+Cenovus+Energy+Inc.+%28CVE%3ACN%29+%28CVE%29+at+Buy/26781616.html</guid>
   <pubDate>Fri, 17 Jul 2026 06:26:35 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	  </item>
  <item>
   <title>Desjardins Starts Cenovus Energy Inc. (CVE:CN) (CVE) at Buy</title>
   <link>http://www.streetinsider.com/Intl+Ratings/Desjardins+Starts+Cenovus+Energy+Inc.+%28CVE%3ACN%29+%28CVE%29+at+Buy/26781616.html</link>
   <description>&lt;p&gt;Desjardins analyst Chris MacCulloch initiates coverage on Cenovus Energy Inc. (CVE:CN) (NYSE: CVE) with a Buy rating and a price target of Cdn$50.00.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/Desjardins+Starts+Cenovus+Energy+Inc.+%28CVE%3ACN%29+%28CVE%29+at+Buy/26781616.html</guid>
   <pubDate>Fri, 17 Jul 2026 06:26:35 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	  </item>
  <item>
   <title>Desjardins Starts Cenovus Energy Inc. (CVE:CN) (CVE) at Buy</title>
   <link>http://www.streetinsider.com/New+Coverage/Desjardins+Starts+Cenovus+Energy+Inc.+%28CVE%3ACN%29+%28CVE%29+at+Buy/26781616.html</link>
   <description>&lt;p&gt;Desjardins analyst Chris MacCulloch initiates coverage on Cenovus Energy Inc. (CVE:CN) (NYSE: CVE) with a Buy rating and a price target of Cdn$50.00.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/New+Coverage/Desjardins+Starts+Cenovus+Energy+Inc.+%28CVE%3ACN%29+%28CVE%29+at+Buy/26781616.html</guid>
   <pubDate>Fri, 17 Jul 2026 06:26:35 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	  </item>
  <item>
   <title>Desjardins Starts Cenovus Energy Inc. (CVE:CN) (CVE) at Buy</title>
   <link>http://www.streetinsider.com/New+Coverage/Desjardins+Starts+Cenovus+Energy+Inc.+%28CVE%3ACN%29+%28CVE%29+at+Buy/26781616.html</link>
   <description>&lt;p&gt;Desjardins analyst Chris MacCulloch initiates coverage on Cenovus Energy Inc. (CVE:CN) (NYSE: CVE) with a Buy rating and a price target of Cdn$50.00.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/New+Coverage/Desjardins+Starts+Cenovus+Energy+Inc.+%28CVE%3ACN%29+%28CVE%29+at+Buy/26781616.html</guid>
   <pubDate>Fri, 17 Jul 2026 06:26:35 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next</title>
   <link>http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</link>
   <description>&lt;p align=&quot;left&quot;&gt;&lt;em&gt;Issued on behalf of Conexeu Sciences Inc.&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;&lt;em&gt;As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it&lt;/em&gt;&lt;/p&gt;    &lt;p align=&quot;left&quot;&gt;RENO, Nevada, July  15, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Energy Metal News&lt;/a&gt; News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html</guid>
   <pubDate>Wed, 15 Jul 2026 08:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ANAB</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CNXU</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FA</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">MPC</category>
   	  </item>
  <item>
   <title>Goldman Sachs names top Canadian oil stocks for free cash flow growth</title>
   <link>http://www.streetinsider.com/Investing/Goldman+Sachs+names+top+Canadian+oil+stocks+for+free+cash+flow+growth/26610217.html</link>
   <description>&lt;img src=&quot;https://i-invdn-com.investing.com/news/LYNXMPEB0S0JW_M.jpg&quot; width=&quot;650&quot; height=&quot;410&quot;  align=&quot;right&quot; alt=&quot;&quot; title=&quot; &quot; /&gt;&lt;p data-path-to-node=&quot;1&quot;&gt;Investing.com -- Goldman Sachs is turning a constructive eye toward the Canadian oil patch, identifying several top upstream stocks positioned to deliver superior total returns. According to a recent note from analysts at the bank, institutional investors looking for exposure to Canada should focus on &lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;&lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;Cenovus Energy Inc&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; (TSX:CVE), &lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;&lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;ConocoPhillips DRC&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; (NLB:ZCOP), &lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;&lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;Canadian Natural&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; Resources Ltd (TSX:CNQ), and &lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;&lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;Ovintiv&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; Inc (TSX:OVV).&lt;/p&gt;
&lt;p data-path-to-node=&quot;1&quot;&gt;&lt;/p&gt;
&lt;p data-path-to-node=&quot;2&quot;&gt;For Cenovus Energy, Goldman</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Goldman+Sachs+names+top+Canadian+oil+stocks+for+free+cash+flow+growth/26610217.html</guid>
   <pubDate>Fri, 05 Jun 2026 13:35:09 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CNQ</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SU</category>
   	  </item>
  <item>
   <title>Goldman Sachs names top Canadian oil stocks for free cash flow growth</title>
   <link>http://www.streetinsider.com/Investing/Goldman+Sachs+names+top+Canadian+oil+stocks+for+free+cash+flow+growth/26610217.html</link>
   <description>&lt;img src=&quot;https://i-invdn-com.investing.com/news/LYNXMPEB0S0JW_M.jpg&quot; width=&quot;650&quot; height=&quot;410&quot;  align=&quot;right&quot; alt=&quot;&quot; title=&quot; &quot; /&gt;&lt;p data-path-to-node=&quot;1&quot;&gt;Investing.com -- Goldman Sachs is turning a constructive eye toward the Canadian oil patch, identifying several top upstream stocks positioned to deliver superior total returns. According to a recent note from analysts at the bank, institutional investors looking for exposure to Canada should focus on &lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;&lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;Cenovus Energy Inc&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; (TSX:CVE), &lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;&lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;ConocoPhillips DRC&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; (NLB:ZCOP), &lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;&lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;Canadian Natural&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; Resources Ltd (TSX:CNQ), and &lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;&lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;Ovintiv&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; Inc (TSX:OVV).&lt;/p&gt;
&lt;p data-path-to-node=&quot;1&quot;&gt;&lt;/p&gt;
&lt;p data-path-to-node=&quot;2&quot;&gt;For Cenovus Energy, Goldman</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Goldman+Sachs+names+top+Canadian+oil+stocks+for+free+cash+flow+growth/26610217.html</guid>
   <pubDate>Fri, 05 Jun 2026 13:35:09 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CNQ</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SU</category>
   	  </item>
  <item>
   <title>Goldman Sachs names top Canadian oil stocks for free cash flow growth</title>
   <link>http://www.streetinsider.com/Investing/Goldman+Sachs+names+top+Canadian+oil+stocks+for+free+cash+flow+growth/26610217.html</link>
   <description>&lt;img src=&quot;https://i-invdn-com.investing.com/news/LYNXMPEB0S0JW_M.jpg&quot; width=&quot;650&quot; height=&quot;410&quot;  align=&quot;right&quot; alt=&quot;&quot; title=&quot; &quot; /&gt;&lt;p data-path-to-node=&quot;1&quot;&gt;Investing.com -- Goldman Sachs is turning a constructive eye toward the Canadian oil patch, identifying several top upstream stocks positioned to deliver superior total returns. According to a recent note from analysts at the bank, institutional investors looking for exposure to Canada should focus on &lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;&lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;Cenovus Energy Inc&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; (TSX:CVE), &lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;&lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;ConocoPhillips DRC&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; (NLB:ZCOP), &lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;&lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;Canadian Natural&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; Resources Ltd (TSX:CNQ), and &lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;&lt;span itemscope=&quot;&quot; itemtype=&quot;http://schema.org/Corporation&quot;&gt;&lt;span itemprop=&quot;name&quot;&gt;Ovintiv&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; Inc (TSX:OVV).&lt;/p&gt;
&lt;p data-path-to-node=&quot;1&quot;&gt;&lt;/p&gt;
&lt;p data-path-to-node=&quot;2&quot;&gt;For Cenovus Energy, Goldman</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Investing/Goldman+Sachs+names+top+Canadian+oil+stocks+for+free+cash+flow+growth/26610217.html</guid>
   <pubDate>Fri, 05 Jun 2026 13:35:09 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">CNQ</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">CVE</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SU</category>
   	  </item>
 </channel>
</rss>
